Base de dados : MEDLINE
Pesquisa : D03.132.577.249.606 [Categoria DeCS]
Referências encontradas : 636 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 64 ir para página                         

  1 / 636 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29232379
[Au] Autor:Deng C; Wang X; Zhu Q; Kang Y; Yang J; Wang H
[Ad] Endereço:Department of Anesthesiology, Sichuan University West China Hospital, Chengdu, Sichuan, China.
[Ti] Título:Comparison of nalbuphine and sufentanil for colonoscopy: A randomized controlled trial.
[So] Source:PLoS One;12(12):e0188901, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Nalbuphine is as effective as morphine as a perioperative analgesic but has not been compared directly with sufentanil in clinical trials. The aims of this study were to compare the efficacy and safety of nalbuphine with that of sufentanil in patients undergoing colonoscopy and to determine the optimal doses of nalbuphine in this indication. METHODS: Two hundred and forty consecutive eligible patients aged 18-65 years with an American Society of Anesthesiologists classification of I-II and scheduled for colonoscopy were randomly allocated to receive sufentanil 0.1 µg/kg (group S), nalbuphine 0.1 mg/kg (group N1), nalbuphine 0.15 mg/kg (group N2), or nalbuphine 0.2 mg/kg (group N3). Baseline vital signs were recorded before the procedure. The four groups were monitored for propofol sedation using the bispectral index, and pain relief was assessed using the Visual Analog Scale and the modified Behavioral Pain Scale for non-intubated patients. The incidences of respiratory depression during endoscopy, nausea, vomiting, drowsiness, and abdominal distention were recorded in the post anesthesia care unit and in the first and second 24-hour periods after colonoscopy. RESULTS: There was no significant difference in analgesia between the sufentanil group and the nalbuphine groups (p>0.05). Respiratory depression was significantly more common in group S than in groups N1 and N2 (p<0.05). The incidence of nausea was significantly higher in the nalbuphine groups than in the sufentanil group in the first 24 hours after colonoscopy (p<0.05). CONCLUSIONS: Nalbuphine can be considered as a reasonable alternative to sufentanil in patients undergoing colonoscopy. Doses in the range of 0.1-0.2 mg/kg are recommended. The decreased risks of respiratory depression and apnea make nalbuphine suitable for patients with respiratory problems.
[Mh] Termos MeSH primário: Analgésicos Opioides/administração & dosagem
Colonoscopia
Nalbufina/administração & dosagem
Sufentanil/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Analgesics, Opioid); AFE2YW0IIZ (Sufentanil); L2T84IQI2K (Nalbuphine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188901


  2 / 636 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28012310
[Au] Autor:Mazák K; Hosztafi S; Kraszni M; Noszál B
[Ad] Endereço:Semmelweis University, Department of Pharmaceutical Chemistry, Research Group of Drugs of Abuse and Doping Agents, Hungarian Academy of Sciences, Hogyes E. u. 9., H-1092 Budapest, Hungary. Electronic address: mazak.karoly@pharma.semmelweis-univ.hu.
[Ti] Título:Physico-chemical profiling of semisynthetic opioids.
[So] Source:J Pharm Biomed Anal;135:97-105, 2017 Feb 20.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Species-specific acid-base and partition equilibrium constants were experimentally determined for the therapeutically important semisynthetic opioid receptor agonist hydromorphone, dihydromorphine, and mixed agonist-antagonist nalorphine and nalbuphine. The acid-base microequilibria were characterized by combining pH-potentiometry and deductive methods using synthesized auxiliary compounds. Independent of the pH, there are approximately 4.8 times as many zwitterionic microspecies than non-charged ones in nalbuphine solutions, while for nalorphine it is the non-charged form that predominates by the same ratio. The non-charged microspecies is the dominant one also in the case of hydromorphone, although its concentration exceeds only 1.3 times that of its zwitterionic protonation isomer. The pH-independent partition coefficients of the individual microspecies were determined by a combination of experimentally measured, pH-dependent, conditional distribution constants and a custom-tailored evaluation method, using highly similar auxiliary compounds. The pH-independent contribution of the zwitterionic microspecies to the distribution constant is 1380, 1070, 3160 and 72,440 times smaller than that of the inherently more lipophilic non-charged one for hydromorphone, dihydromorphine, nalbuphine and nalorphine, respectively.
[Mh] Termos MeSH primário: Analgésicos Opioides/química
Fenômenos Químicos
Di-Hidromorfina/química
Hidromorfona/química
Nalbufina/química
Nalorfina/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); C3S5FRP6JW (Dihydromorphine); L2T84IQI2K (Nalbuphine); Q812464R06 (Hydromorphone); U59WB2WRY2 (Nalorphine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170524
[Lr] Data última revisão:
170524
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161225
[St] Status:MEDLINE


  3 / 636 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27906936
[Au] Autor:Bakri MH; Ismail EA; Abd-Elshafy SK
[Ad] Endereço:Associate professor of Anesthesia, Faculty of Medicine, Assiut University, Assuit, Egypt.
[Ti] Título:Analgesic Effect of Nalbuphine When Added to Intravenous Regional Anesthesia: A Randomized Control Trial.
[So] Source:Pain Physician;19(8):575-581, 2016 Nov-Dec.
[Is] ISSN:2150-1149
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Different adjuvant drugs are currently added to lidocaine for intravenous regional anesthesia (IVRA) to decrease tourniquet and postoperative pain. OBJECTIVE: The aim of the study was to examine the effect of nalbuphine when added toIVRA. STUDY DESIGN: Prospective, randomized, double-blind, controlled clinical trial. SETTING: Assiut University Hospitals. METHODS: One hundred-six adult patients scheduled for unilateral hand surgery under IVRA were randomized into 2 equal groups. The lidocaine-nalbuphine (LN) group received nalbuphine plus lidocaine and the lidocaine (L) group received lidocaine. A tourniquet and postoperative pain were assessed using a visual analogue scale (VAS). The following parameters were measured: onset and recovery time for both sensory and motor blocks, intra- and postoperative analgesic consumption, time to first analgesic request, postoperative nausea and/or vomiting (PONV), hemodynamics, and cortisol levels. RESULTS: Early tourniquet and postoperative pain were significantly lower in the LN group. The onset time for both sensory and motor blocks was significantly shorter in the LN group. In addition, the recovery time for both sensory and motor blocks was longer in the LN group. Intra- and postoperative fentanyl consumption was significantly lower in the LN group with no significance in postoperative diclofenac consumption. The patient first analgesic request was significantly delayed in the LN group (P < 0.0001). There were no significant differences between the 2 groups in PONV, hemodynamic parameters abnormalities, medications adverse events or cortisol levels. LIMITATIONS: The inclusion of a study group in which the nalbuphine administered systemically could determine whether its beneficial effects were due to its local or systemic action. CONCLUSIONS: Nalbuphine decreases early tourniquet and postoperative pain after IVRA and delays the need for analgesic rescue. In addition, nalbuphine accelerates the onset and prolongs the recovery time for both sensory and motor blocks with no significant adverse events. However, it has no effect on postoperative cortisol levels.Key words: Intravenous, regional anesthesia, lidocaine, nalbuphine, pain, postoperative.
[Mh] Termos MeSH primário: Analgésicos Opioides/uso terapêutico
Anestésicos Locais/uso terapêutico
Lidocaína/uso terapêutico
Nalbufina/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Anestesia por Condução
Método Duplo-Cego
Feminino
Mãos/cirurgia
Seres Humanos
Masculino
Medição da Dor
Dor Pós-Operatória
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Anesthetics, Local); 98PI200987 (Lidocaine); L2T84IQI2K (Nalbuphine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170721
[Lr] Data última revisão:
170721
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161202
[St] Status:MEDLINE


  4 / 636 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27504867
[Au] Autor:van Niel JC; Schneider J; Tzschentke TM
[Ad] Endereço:Grünenthal GmbH, Global Late Stage Clinical Development, Aachen, Germany.
[Ti] Título:Efficacy of Full µ-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence.
[So] Source:Drug Res (Stuttg);66(11):562-570, 2016 Nov.
[Is] ISSN:2194-9387
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Buprenorphine and the mixed agonists/antagonists nalbuphine and pentazocine, formerly classified as µ-opioid (MOP) receptor antagonists, have more recently been shown to be partial to full agonists of the human MOP receptor. These receptors do not necessarily have to be maximally activated for a full physiological response. Partial agonists can also sufficiently stimulate signaling processes leading to a full analgesic response, as shown by the effectiveness of buprenorphine, nalbuphine and pentazocine in animal pain models and in clinical settings where these drugs induce analgesia with full efficacy without a ceiling effect. Submaximal doses of MOP receptor analgesics combined with submaximal doses of buprenorphine, pentazocine, or nalbuphine result in additive to over-additive antinociceptive effects in animal experiments. Only when doses are given that exceed the therapeutic dose range may the antinociceptive effect be reduced to the effect of either opioid alone. The analgesic effects of pentazocine and nalbuphine combined with morphine are reported to be additive or over-additive in various clinical pain conditions. Buprenorphine, which clinically behaves as a full MOP receptor agonist for pain relief, can be combined with full opioid agonists without precipitating withdrawal. Thus, the overall evidence on the analgesic effects of buprenorphine, pentazocine or nalbuphine combined with opioid analgesics under various clinical pain conditions contradicts the consensus that these compounds diminish MOP receptor analgesia when co-administered with a full MOP receptor agonist.
[Mh] Termos MeSH primário: Analgésicos Opioides/farmacologia
Analgésicos Opioides/uso terapêutico
Buprenorfina/farmacologia
Buprenorfina/uso terapêutico
Antagonistas de Entorpecentes/farmacologia
Antagonistas de Entorpecentes/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Nalbufina/farmacologia
Nalbufina/uso terapêutico
Dor/tratamento farmacológico
Pentazocina/farmacologia
Pentazocina/uso terapêutico
Receptores Opioides/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Narcotic Antagonists); 0 (Receptors, Opioid); 40D3SCR4GZ (Buprenorphine); L2T84IQI2K (Nalbuphine); RP4A60D26L (Pentazocine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170330
[Lr] Data última revisão:
170330
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160810
[St] Status:MEDLINE


  5 / 636 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26878827
[Au] Autor:Haw AJ; Meyer LC; Fuller A
[Ad] Endereço:Brain Function Research Group, Faculty of Health Sciences, School of Physiology, University of the Witwatersrand, Joahnnesburg, South Africa.
[Ti] Título:Nalbuphine and butorphanol reverse opioid-induced respiratory depression but increase arousal in etorphine-immobilized goats (Capra hircus).
[So] Source:Vet Anaesth Analg;43(5):539-48, 2016 Sep.
[Is] ISSN:1467-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To evaluate and compare the efficacy of two opioid agonist-antagonists, nalbuphine and butorphanol, in reversing etorphine-induced respiratory depression in immobilized goats. STUDY DESIGN: Prospective, crossover, experimental trial conducted at 1753 m.a.s.l. ANIMALS: Eight adult female Boer goats (Capra hircus). METHODS: Eight minutes following immobilization with an intramuscular injection of 0.1 mg kg(-1) etorphine, goats were given one of nalbuphine (0.8 mg kg(-1) ), butorphanol (0.1 mg kg(-1) ) or sterile water intravenously, in random order in three trials. Respiratory rate (fR ), ventilation, tidal volume, oxygen consumption (VË™O2 ) and carbon dioxide production (VË™CO2 ) were measured continuously. Arterial blood samples to determine PaO2 and PaCO2 were taken 2 minutes before and at 5 minute intervals after etorphine administration for 25 minutes. RESULTS: Both nalbuphine and butorphanol increased mean PaO2 from 44 mmHg (5.9 kPa) to 63 mmHg (8.4 kPa) after etorphine administration. Butorphanol, but not nalbuphine, also corrected hypopnea and hypoventilation such that fR increased from 13 ± 4 to 21 ± 7 breaths minute(-1) (compared with 16 ± 6 breaths minute(-1) following nalbuphine) and ventilation increased from 4.69 ± 3.04 to 6.91 ± 4.42 L minute(-1) following butorphanol administration. Despite decreases in PaCO2 following nalbuphine and butorphanol, PaCO2 remained elevated compared with pre-immobilization values [nalbuphine: 34 ± 3 mmHg (4.5 ± 0.3 kPa); butorphanol: 34 ± 2 mmHg (4.5 ± 0.3 kPa)] throughout the immobilization. Both agents also decreased the level of immobilization, and increased VË™O2 and VË™CO2 . CONCLUSIONS: Nalbuphine and butorphanol significantly improved respiratory function in immobilized goats, with butorphanol eliciting a greater positive response than nalbuphine. However, both opioid agonist-antagonists partly reversed etorphine-induced immobilization. CLINICAL RELEVANCE: Butorphanol and nalbuphine can be used to improve respiratory parameters in etorphine-immobilized wildlife, with butorphanol being more effective, but unwanted arousal can occur.
[Mh] Termos MeSH primário: Analgésicos Opioides/farmacologia
Butorfanol/farmacologia
Etorfina/farmacologia
Nalbufina/farmacologia
Antagonistas de Entorpecentes/farmacologia
[Mh] Termos MeSH secundário: Animais
Estudos Cross-Over
Feminino
Cabras
Imobilização
Estudos Prospectivos
Insuficiência Respiratória/induzido quimicamente
Insuficiência Respiratória/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Narcotic Antagonists); 42M2Y6NU9O (Etorphine); L2T84IQI2K (Nalbuphine); QV897JC36D (Butorphanol)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170408
[Lr] Data última revisão:
170408
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160217
[St] Status:MEDLINE
[do] DOI:10.1111/vaa.12343


  6 / 636 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26650717
[Au] Autor:Jannuzzi RG
[Ti] Título:Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature.
[So] Source:Clin J Pain;32(1):87-93, 2016 Jan.
[Is] ISSN:1536-5409
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Opioid-induced pruritus is a common side effect of opioid treatment in patients with acute pain associated with surgery or childbirth. There are several options available to treat opioid-induced pruritus, including nalbuphine. However, it is not known whether nalbuphine offers greater efficacy in treating pruritus without attenuation of analgesia and an increase in the incidence of adverse outcomes. METHODS: A systematic search of studies assessing treatment efficacy of nalbuphine was conducted through Medline, PubMed, Cochrane Library, CINAHL, and ProQuest databases. The primary outcome was reduction of pruritus, whereas the secondary outcomes included analgesia and adverse outcomes. RESULTS: Ten studies that met all inclusion criteria were identified, 9 of which were randomized controlled trials and 1 case report. The incidence of pruritus was higher among patients receiving neuraxial opioids than those with the intravenous route. Nalbuphine provided greater efficacy in treating opioid-induced pruritus when compared with placebo, control, or other pharmacologic agents such as diphenhydramine, naloxone, and propofol. There was no attenuation of analgesia or increase in sedation with low-dose nalbuphine treatment­25% to 50% of the dose to treat pain, that is, 2.5 to 5 mg versus 10 mg intravenously. Further, nalbuphine was associated with reduction of nausea or vomiting, and reversal of respiratory depression. CONCLUSIONS: Nalbuphine is superior in treating opioid-induced pruritus when compared with placebo, control, diphenhydramine, naloxone, or propofol in patients receiving neuraxial opioids for acute pain related to surgery or childbirth. Therefore, it is recommended that nalbuphine should be used as a first-line treatment of opioid-induced pruritus.
[Mh] Termos MeSH primário: Analgésicos Opioides/efeitos adversos
Analgésicos Opioides/uso terapêutico
Nalbufina/uso terapêutico
Prurido/induzido quimicamente
Prurido/tratamento farmacológico
[Mh] Termos MeSH secundário: Dor Aguda/tratamento farmacológico
Seres Humanos
Prurido/epidemiologia
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Analgesics, Opioid); L2T84IQI2K (Nalbuphine)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160321
[Lr] Data última revisão:
160321
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151210
[St] Status:MEDLINE


  7 / 636 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26662139
[Au] Autor:Mateshuk-Vatseba L; Pidvalna U; Kost A
[Ad] Endereço:Department of Normal Anatomy, Danylo Halytskyi Lviv National Medical University, Lviv, Ukraine; uljaska.p@gmail.com.
[Ti] Título:Peculiarities of vascular tunic microstructure of the white rat eyeball under the effect of opioid.
[So] Source:Rom J Morphol Embryol;56(3):1057-62, 2015.
[Is] ISSN:1220-0522
[Cp] País de publicação:Romania
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: This article deals with determination of changes in the structural organization of vascular tunic of the eyeball under the effect of opioid. MATERIALS AND METHODS: The study was carried out on 24 mature white male rats aged 3.0-4.5 months and 170-280 g weight. The research material included histological specimen and semi-thin sections of white rats' eyeball vascular tunic. For the histological study, microscopic sections of the eyeball were stained with Hematoxylin and Eosin, Heidenhain's Azan trichrome. Specimens were studied and photographed with microscope magnification: ×600, ×1000. RESULTS: The first signs of microstructure disorder in all parts of vascular tunic of the eyeball are noticeable after two weeks of nalbuphine injection to the white rats. During the next four weeks of the experiment, the pathological changes increase and are manifested by the swelling and polymorphonuclear infiltration of the iris, ciliary body, choroid and by deep destructive changes of eyeball hemomicrocirculatory bloodstream. Histological and ultramicroscopic studies of the white rats' eyeball vascular tunic after six weeks of nalbuphine injections showed deep destructive changes in the structure of all parts of vascular tunic. CONCLUSIONS: Our study demonstrated a negative effect of the prolonged injection of opioid in the experiment on the state of microstructural organization of the eyeball vascular tunic. Development of angiopathy is the triggering for occurrence of destructive changes in the eyeball under the effect of opioid.
[Mh] Termos MeSH primário: Analgésicos Opioides/farmacologia
Olho/irrigação sanguínea
Olho/efeitos dos fármacos
[Mh] Termos MeSH secundário: Analgésicos Opioides/administração & dosagem
Animais
Corioide/efeitos dos fármacos
Corioide/patologia
Corpo Ciliar/efeitos dos fármacos
Corpo Ciliar/patologia
Olho/patologia
Iris/efeitos dos fármacos
Iris/patologia
Masculino
Nalbufina/administração & dosagem
Nalbufina/farmacologia
Ratos
Retina/efeitos dos fármacos
Retina/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); L2T84IQI2K (Nalbuphine)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151215
[St] Status:MEDLINE


  8 / 636 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Laus, José Luiz
Texto completo SciELO Brasil
[PMID]:26222100
[Au] Autor:Silva ML; Ribeiro AP; Silva GA; Sanchez IX; Renzo R; Uscategui R; Lima TB; Aldrovani M; Laus JL
[Ad] Endereço:Department of Medicine and Surgery, College of Agricultural and Veterinarian Sciences, Universidade de São Paulo, Jaboticabal, SP, Brazil.
[Ti] Título:Expressions of matrix metalloproteinases-1 and -9 and opioid growth factor in rabbit cornea after lamellar keratectomy and treatment with 1% nalbuphine.
[So] Source:Arq Bras Oftalmol;78(3):141-5, 2015 May-Jun.
[Is] ISSN:1678-2925
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:PURPOSES: To evaluate the effects of nalbuphine 1% on the expression of metalloproteinase 1 (MMP-1), metalloproteinase 9 (MMP-9), and opioid growth factor (OGF) in rabbit corneas after lamellar keratectomy. METHODS: The rabbits were assigned to two groups: group nalbuphine (GN, n=30), which received 30 µL of nalbuphine 1% in 4 daily applications at regular intervals until corneal epithelialization, and group control (GC, n=30), which received physiological saline solution under the same conditions adopted in GN. The corneas were collected for immunohistochemistry on days 1, 3, 5, 7, and 9 after lamellar keratectomy, and the expressions of MMP-1, MMP-9, and OGF were analyzed. RESULTS: The expressions of MMP-1 and MMP-9 increased until day 5 of the evaluation, with no differences observed between GN and GC (p>0.05). On days 7 and 9, significant reductions were observed in the expression of MMP-1 (p<0.01), with no differences observed between GN and GC (p>0.05). The expression of OGF was constant in all periods (p>0.05), restricted to the corneal epithelium, and there was no difference between the groups (p>0.05). CONCLUSIONS: The study results showed that nalbuphine 1% did not alter the expression patterns of MMP-1, MMP-9, and OGF in rabbit corneas after lamellar keratectomy.
[Mh] Termos MeSH primário: Analgésicos Opioides/farmacologia
Epitélio Anterior/efeitos dos fármacos
Metaloproteinase 1 da Matriz/efeitos dos fármacos
Metaloproteinase 9 da Matriz/efeitos dos fármacos
Nalbufina/farmacologia
Receptores Opioides/efeitos dos fármacos
[Mh] Termos MeSH secundário: Analgésicos Opioides/administração & dosagem
Animais
Substância Própria/metabolismo
Substância Própria/patologia
Epitélio Anterior/metabolismo
Imuno-Histoquímica
Masculino
Metaloproteinase 1 da Matriz/metabolismo
Metaloproteinase 9 da Matriz/metabolismo
Modelos Animais
Nalbufina/administração & dosagem
Coelhos
Receptores Opioides/metabolismo
Procedimentos Cirúrgicos Refrativos/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Receptors, Opioid); EC 3.4.24.35 (Matrix Metalloproteinase 9); EC 3.4.24.7 (Matrix Metalloproteinase 1); L2T84IQI2K (Nalbuphine)
[Em] Mês de entrada:1512
[Cu] Atualização por classe:150730
[Lr] Data última revisão:
150730
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150730
[St] Status:MEDLINE


  9 / 636 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26165241
[Au] Autor:Kubica-Cielinska A; Zielinska M
[Ad] Endereço:Department of Pediatric Anesthesiology and Intensive Care, University Hospital in Wroclaw, Poland. annacielinska@gmail.com.
[Ti] Título:The use of nalbuphine in paediatric anaesthesia.
[So] Source:Anaesthesiol Intensive Ther;47(3):252-6, 2015.
[Is] ISSN:1731-2515
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Nalbuphine is an agonist-antagonist opioid. It causes analgesic and sedative effect and because of ceiling effect it does not cause a respiratory depression. In a perioperative therapy of paediatric patients it may be used for premedication, sedation during diagnostic procedures as well as for postoperative pain treatment. It reverses adverse reactions of other opioids such as itch or urinary retention, not significantly influencing its analgetic properties. After sevoflurane anaesthesia of small children, it reduces the incidences of emergence agitation. Nalbuphine is considered a safe drug, which causes nausea and vomiting less frequently than other opioids. Analgesic effect, the ability to provide moderate sedation and a large margin of safety make that analgesic often used for paediatric patients.
[Mh] Termos MeSH primário: Analgésicos Opioides/administração & dosagem
Nalbufina/administração & dosagem
Antagonistas de Entorpecentes/administração & dosagem
[Mh] Termos MeSH secundário: Analgésicos Opioides/efeitos adversos
Anestesia/efeitos adversos
Anestesia/métodos
Criança
Seres Humanos
Éteres Metílicos/administração & dosagem
Éteres Metílicos/efeitos adversos
Nalbufina/efeitos adversos
Antagonistas de Entorpecentes/efeitos adversos
Dor Pós-Operatória/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Methyl Ethers); 0 (Narcotic Antagonists); 38LVP0K73A (sevoflurane); L2T84IQI2K (Nalbuphine)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:150713
[Lr] Data última revisão:
150713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150714
[St] Status:MEDLINE
[do] DOI:10.5603/AIT.2015.0036


  10 / 636 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26039709
[Au] Autor:Zeng Z; Lu J; Shu C; Chen Y; Guo T; Wu QP; Yao SL; Yin P
[Ad] Endereço:Medical Student, Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology.
[Ti] Título:A comparision of nalbuphine with morphine for analgesic effects and safety : meta-analysis of randomized controlled trials.
[So] Source:Sci Rep;5:10927, 2015 Jun 03.
[Is] ISSN:2045-2322
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Although morphine is the standard opioid analgesic for pain control and has been widely used, certain drug-induced adverse effects have been reported as intolerable and need to be addressed. Nalbuphine may have a few advantages over morphine in this respect. We aimed to describe the effect of nalbuphine as well as its safety compared to morphine by analyzing published randomized controlled trials (RCTs) with meta-analysis approach. We analysed 15 trials (820 patients). Overall, there was no evidence to show that the effect of pain relief had any difference between nalbuphine and morphine (pooled relative risks [RRs], 1.01; 95% CI, 0.91 to 1.11; P = 0.90). On the other hand, the incidences of pruritus, nausea, vomiting, respiratory depression were significantly lower in nalbuphine group compared with morphine group, and the pooled RRs were 0.78(95%CI, 0.602-0.997; P = 0.048) for nausea, 0.65(95%CI, 0.50-0.85; P = 0.001) for vomiting, 0.17(95%CI, 0.09-0.34; P < 0.0001) for pruritus, and 0.27(95%CI, 0.12-0.57; P = 0.0007) for respiratory depression. The analgesic efficacy of nalbuphine is comparable to morphine, but nalbuphine provides a better safety profile than morphine in the aspect of certain side-effects, especially related to pruritus and respiratory depression.
[Mh] Termos MeSH primário: Analgésicos Opioides/uso terapêutico
Morfina/uso terapêutico
Nalbufina/uso terapêutico
Manejo da Dor
[Mh] Termos MeSH secundário: Analgésicos Opioides/efeitos adversos
Seres Humanos
Morfina/efeitos adversos
Nalbufina/efeitos adversos
Razão de Chances
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Analgesics, Opioid); 76I7G6D29C (Morphine); L2T84IQI2K (Nalbuphine)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:150612
[Lr] Data última revisão:
150612
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150604
[St] Status:MEDLINE
[do] DOI:10.1038/srep10927



página 1 de 64 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde